Kenneth Dickstein
A5101709015- Heart Failure Treatment and Management
- Cardiac pacing and defibrillation studies
- Cardiovascular Function and Risk Factors
- Cardiac Arrhythmias and Treatments
- Cardiac electrophysiology and arrhythmias
- Atrial Fibrillation Management and Outcomes
- Erythropoietin and Anemia Treatment
- Iron Metabolism and Disorders
- Cardiovascular and exercise physiology
- Health Systems, Economic Evaluations, Quality of Life
- Cardiac Structural Anomalies and Repair
- GDF15 and Related Biomarkers
- Blood Pressure and Hypertension Studies
- Potassium and Related Disorders
- Cardiac Fibrosis and Remodeling
- Cardiac Imaging and Diagnostics
- Peptidase Inhibition and Analysis
- Diabetes Treatment and Management
- Cardiovascular Effects of Exercise
- Cardiac Valve Diseases and Treatments
- Nutrition and Health in Aging
- Medication Adherence and Compliance
- Hormonal Regulation and Hypertension
- Mechanical Circulatory Support Devices
- Heart Rate Variability and Autonomic Control
Stavanger University Hospital
2016-2025
University of Bergen
2016-2025
University of Stavanger
2005-2023
University Medical Center Groningen
2009-2019
Aalborg University
2019
Paris Cardiovascular Research Center
2019
Inserm
2019
Resonance Research (United States)
2019
University of Oxford
2019
John Radcliffe Hospital
2019
of the individual patients, in consultation with that patient, and where appropriate necessary patient's guardian or carer.It is also health professional's responsibility to verify rules regulations applicable drugs devices at time prescription.
Non-thrombotic PE does not represent a distinct clinical syndrome. It may be due to variety of embolic materials and result in wide spectrum presentations, making the diagnosis difficult. With exception severe air fat embolism, haemodynamic consequences non-thrombotic emboli are usually mild. Treatment is mostly supportive but differ according type material severity.
Diastolic heart failure (DHF) currently accounts for more than 50% of all patients. DHF is also referred to as with normal left ventricular (LV) ejection fraction (HFNEF) indicate that HFNEF could be a precursor reduced LVEF. Because improved cardiac imaging and because widespread clinical use plasma levels natriuretic peptides, diagnostic criteria needed updated. The diagnosis requires the following conditions satisfied: (i) signs or symptoms failure; (ii) mildly abnormal systolic LV...
Iron deficiency may impair aerobic performance. This study aimed to determine whether treatment with intravenous iron (ferric carboxymaltose) would improve symptoms in patients who had heart failure, reduced left ventricular ejection fraction, and deficiency, either or without anemia.
Nesiritide is approved in the United States for early relief of dyspnea patients with acute heart failure. Previous meta-analyses have raised questions regarding renal toxicity and mortality associated this agent.We randomly assigned 7141 who were hospitalized failure to receive either nesiritide or placebo 24 168 hours addition standard care. Coprimary end points change at 6 hours, as measured on a 7-point Likert scale, composite point rehospitalization death within 30 days.Patients...
Guidelines and Expert Consensus Documents summarize evaluate all currently available evidence on a particular issue with the aim to assist physicians in selecting best management strategies for typical patient, suffering from given condition, taking into account impact outcome, as well risk–benefit ratio of diagnostic or therapeutic means. are no substitutes textbooks. The legal implications medical guidelines have been discussed previously. A great number issued recent years by European...
Cardiac-resynchronization therapy (CRT) reduces morbidity and mortality in chronic systolic heart failure with a wide QRS complex. Mechanical dyssynchrony also occurs patients narrow complex, which suggests the potential usefulness of CRT such patients.We conducted randomized trial involving 115 centers to evaluate effect New York Heart Association class III or IV failure, left ventricular ejection fraction 35% less, duration less than 130 msec, echocardiographic evidence dyssynchrony. All...
8.1.6.1.7. Sotalol . 8.1.6.2. Drugs with unproven efficacy or no longer recommended .8.1.6.2.1.Digoxin .8.1.6.2.2.Procainamide .8.1.6.2.3.Quinidine .8.1.6.2.4.Verapamil and diltiazem .8.1.7.Out-of-hospital initiation of antiarrhythmic drugs in patients atrial fibrillation
Corrigendum to: ‘ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation–executive summary. A report American College Cardiology/American Heart Association Task Force on practice and European …
One large study, MIRACLE ICD 9 and one meta-analysis 15 support the choice of a CRT-D in patients NYHA class III/IV, with LVEF ≤35%, QRS width ≥120 ms conventional indication for an ICD.Key points † New: LV dilatation no longer required recommendation.† IV should be ambulatory.† reasonable expectation survival good functional status .1 year CRT-D.† Evidence is strongest typical LBBB.† Similar level evidence CRT-P CRT-D.
Abstract Aims The current pandemic coronavirus SARS-CoV-2 infects a wide age group but predominantly elderly individuals, especially men and those with cardiovascular disease. Recent reports suggest an association use of renin–angiotensin–aldosterone system (RAAS) inhibitors. Angiotensin-converting enzyme 2 (ACE2) is functional receptor for coronaviruses. Higher ACE2 concentrations might lead to increased vulnerability in patients on RAAS Methods results We measured 1485 537 women heart...
The Committee for Practice Guidelines (CPG) of the European Society Cardiology recognizes that new evidence from clinical research trials may impact on current recommendations. heart failure (HF) guidelines1 were published in 2008 and cardiac pacing guidelines 2007.2 In order to keep these up date, it would be appropriate modify recommendations levels according most recent trial evidence. This Focused Update use devices 2010 is first publication its kind CPG. Practice Guideline should...
Despite clear guidelines recommendations, most patients with heart failure and reduced ejection-fraction (HFrEF) do not attain guideline-recommended target doses. We aimed to investigate characteristics for treatment-indication-bias corrected clinical outcome of HFrEF that did reach recommended treatment doses ACE-inhibitors/Angiotensin receptor blockers (ARBs) and/or beta-blockers.BIOSTAT-CHF was specifically designed study uptitration ACE-inhibitors/ARBs beta-blockers in 2516 from 69...
РЕКОМЕНДАЦИИ ПО ЛЕЧЕНИЮ ЕВРОПЕЙСКОГО ОБЩЕСТВА КАРДИОЛОГОВ ДИАГНОСТИКЕ И ОСТРОЙ